Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Topics

Renal cell carcinoma · Renal cell carcinoma · ESMO Clinical Practice Guideline · diagnosis · treatment · follow-up · incidence · malignancy · clear cell renal cell carcinoma · non-clear cell renal cell carcinoma · papillary renal cell carcinoma · chromophobe renal cell carcinoma · sarcomatoid differentiation · VHL gene · mTOR pathway · VEGF pathway · tyrosine kinase inhibitors · Immune checkpoint inhibition · PD-1 · PD-L1 · CTLA-4 · sunitinib · pazopanib · nivolumab · ipilimumab · pembrolizumab · axitinib · cabozantinib · lenvatinib · everolimus · temsirolimus · bevacizumab · combination immunotherapy · nephrectomy · cytoreductive nephrectomy · partial nephrectomy · metastasectomy · ablative therapies · stereotactic body radiotherapy · Targeted therapy · first-line treatment · second-line therapy · prognostic risk groups · IMDC risk score · MSKCC risk score · Biomarker · staging · TNM classification · metastatic renal cell carcinoma · localized renal cell carcinoma · Adjuvant therapy · surveillance · hereditary renal cell carcinoma · von Hippel-Lindau disease · angiogenesis · Tumor microenvironment · clinical trial · Overall survival · progression-free survival · Objective response rate